Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, addresses the regulation of therapeutic goods within Australia to ensure public health and safety. This Act provides the legislative framework for the control and oversight of therapeutic goods, including medicines, medical devices, and other health-related products. The Therapeutic Goods Administration (TGA), a department within the Australian Government's Department of Health, administers the Act and its provisions to maintain high standards of quality, safety, and efficacy for therapeutic goods available in the Australian market. This legislative initiative was introduced to fill the gap in regulating the manufacture, importation, and distribution of therapeutic goods, thereby protecting consumers from potentially harmful products and ensuring that only products that meet stringent health and safety standards are available for use. The policy objective of the Therapeutic Goods Act 1989 is to safeguard public health by ensuring that therapeutic goods available in Australia meet necessary quality, safety, and efficacy standards. This is achieved through a rigorous licensing and approval process, which includes granting licences to manufacturers who meet the specified criteria and standards set forth in the Act. The TGA, as the enforcing body, plays a critical role in implementing these regulations and ensuring compliance among manufacturers and other stakeholders. The publication of the list of manufacturers granted licences under Section 38 of the Act is a part of this ongoing effort to maintain transparency and accountability in the therapeutic goods industry.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities engaged in the manufacture, importation, supply, or distribution of therapeutic goods within Australia. The Act is administered by the Therapeutic Goods Administration (TGA), an agency of the Commonwealth of Australia, and its primary objective is to ensure that therapeutic goods available in Australia are of acceptable quality, performance, and safety. Specifically, the Act applies to companies and individuals who are involved in the production, handling, or marketing of therapeutic goods, which include medicines, medical devices, blood and blood components, tissues, and certain other health-related products. The geographic reach of the Act is national, extending to the entire Commonwealth of Australia, and it includes territories under the jurisdiction of the Australian government. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods, as noted in the gazetted notice, underscores the regulatory framework governing the industry. The notice specifies the licence numbers and addresses of companies such as Symbio Laboratories Pty Ltd, SCP Alliance Sydney Pty Ltd, and Pharmako Biotechnologies Pty Ltd, indicating their approval to manufacture therapeutic goods. While the Act aims to maintain stringent standards, certain exclusions or exemptions may apply, often detailed in subordinate instruments or specific guidelines issued by the TGA. These regulations ensure that the therapeutic goods market remains safe and effective for consumers, while also allowing for flexibility and innovation within the industry.

Key Provisions

Section 38 of the Therapeutic Goods Act 1989 (the Act) provides the authority for the Secretary to grant licences for the manufacture of therapeutic goods. The Act mandates that certain entities must hold a licence to legally manufacture therapeutic goods in Australia, ensuring these goods meet necessary safety, efficacy, and quality standards. Specifically, Section 38 allows the Secretary to issue licences to qualified entities, as evidenced by the recent publication by Katherine Clark, Delegate of the Secretary of the Department of Health Therapeutic Goods Administration. In this instance, Symbio Laboratories Pty Ltd, SCP Alliance Sydney Pty Ltd, and Pharmako Biotechnologies Pty Ltd have been granted licences to manufacture therapeutic goods, with each entity receiving a unique licence number. Entities granted a licence under Section 38 of the Act must adhere to stringent obligations and requirements. These include maintaining comprehensive records of their manufacturing processes, ensuring the quality and safety of the therapeutic goods produced, and complying with any conditions set by the Secretary. The licence holders are also required to submit regular reports to the Therapeutic Goods Administration (TGA) detailing their manufacturing activities and any incidents that may affect the safety or quality of the goods. Additionally, the licence holders must ensure that their manufacturing practices comply with the standards set out in the Therapeutic Goods Regulations 1990, which provide further detail on the quality and safety requirements for therapeutic goods. Failure to comply with the provisions of the Act or the conditions of the licence can result in serious consequences. Under Section 132 of the Act, a person who contravenes any provision of the Act or the regulations may be liable to face criminal charges, with potential penalties including substantial fines and imprisonment. Specifically, for manufacturing therapeutic goods without a valid licence, an individual officer may face a fine of up to $222,222 and/or imprisonment for up to five years, while a body corporate may be fined up to $1,111,110. Furthermore, civil penalties, including infringement notices and court actions, may also be pursued for breaches of the Act or the conditions of a licence, with penalties varying depending on the severity and nature of the breach. The Act aims to ensure that all therapeutic goods available in Australia are safe, of high quality, and meet the necessary regulatory standards.